Palisade Bio, Inc. (PALI) Reports Early IBD Signals for PALI-2108; Phase 2 Studies Advancing

Palisade Bio (PALI) shares rose 9% after presenting early clinical data for PALI-2108, showing improvements in Crohn's disease patients. The Phase 1b study reported a 47.5% decrease in disease activity and 58.8% reduction in inflammation marker. The company is conducting further Phase 2 trials. PALI stock is currently at $1.46, up from its 52-week range of $1.32-$2.86.

Palisade Bio (NASDAQ:PALI) reported early-stage trial results for PALI-2108, showing reductions in Crohn's disease activity measures in a small, 5-patient study. The drug demonstrated decreases in disease scores and inflammation markers, with mild adverse events. The company is advancing to Phase 2 studies. Results are preliminary and require further validation.

Palisade Bio (PALI) reported that its experimental drug PALI-2108 showed a 58.8% reduction in a gut inflammation marker in five Crohn's disease patients after 14 days. The Phase 1b study also demonstrated endoscopic improvement and reduced intestinal inflammation. The company is advancing Phase 2b studies for ulcerative colitis and initiating a Phase 2a study for Crohn's disease.

HC Wainwright & Co. maintained a Buy rating on Palisade Bio, setting a $7 price target, implying a 340.3% upside from the Oct 12 close of $1.59. The firm cited promising clinical data for PALI-2108, showing 40% endoscopic response in 14 days, and a favorable safety profile.

Palisade Bio (PALI) presented clinical data on PALI-2108, an investigational drug for ulcerative colitis and Crohn's disease, at the ACG 2026 Annual Scientific Meeting. Two studies showed promising results, with all patients achieving clinical response in a 7-day ulcerative colitis study and a 47.5% mean reduction in a 14-day Crohn's disease study. The company is conducting a Phase 2 study in ulcerative colitis. PALI-2108 has not been approved for any indication.

Palisade Bio (PALI) presented new data on PALI-2108 at ACG 2026, showing targeted intestinal exposure and early clinical activity. The data supports ongoing Phase 2 trials for ulcerative colitis and Crohn's disease. Two abstracts received ACG Presidential Poster Awards.